You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.
-
Novel Rewarming Technique for Cyropreserved Tissue
SBC: TDA Research, Inc. Topic: DHP15014TDAs proposes to develop a novel RF heating process for rewarming cryogenically preserved tissues and organs. TDAs approach is to optimize the RF frequency and power, along with the chemical composition, size and morphology of infused nanoparticles so that they heat tissue samples rapidly and uniformly. In this manner, the cryoprotectant solutions pass from the vitrified state to the liquid stat ...
SBIR Phase I 2015 Department of DefenseDefense Health Program -
IGF OT IGF TREATMENT OF TUBERCULOSIS WITH INHALED DELIVERY OF CLOFAZIMINE
SBC: AEROPHASE INC Topic: NIAIDNot Available
SBIR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF TITLE CHEMO ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED COMPLEX TYPE N GLYCANS
SBC: CHEMILY, LLC Topic: NCINot Available
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF SMOKESCREEN GENETIC SCREENING TOOL FOR TOBACCO DEPENDENCE and TREATMENT APPROACHES POP MOD SUPPLEMENT WITHIN SCOPE AND EXTENSION
SBC: BioRealm LLC Topic: NIDANot Available
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
IGF OT IGF CONTRACT TITLE RADIATION MODULATORS FOR HEAD AND NECK CANCERPOP
SBC: SuviCa, Inc. Topic: NCINot Available
SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel Trap for Ticks and Fleas Incorporating a CO2 Generator
SBC: TDA Research, Inc. Topic: DHP13007Military personnel must be protected from diseases transmitted by ticks and fleas, including Lyme disease. Effective surveillance of tick and flea vectors is vital to determine the population present, whether they are carrying disease, and whether control campaigns are working. Unfortunately, current surveillance tools are ineffective. In Phase I TDA designed, prototyped, and tested a novel ti ...
SBIR Phase II 2015 Department of DefenseDefense Health Program -
Smartphone Technology for Parents and Teens: Improving Vaccination Uptake
SBC: KLEIN BUENDEL, INC Topic: NICHDDESCRIPTION provided by applicant Vaccinations for adolescents in the U S tetanus diphtheria and acellular pertussis Tdap meningococcal conjugate vaccine MCV Human Papillomavirus HPV vaccines Gardasil and Cervarex remain well below the Centers for Disease Control and Prevention CDC goals and especially so for the HPV vaccines These vaccine deficits are pronounced among minor ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Development of Isotopically Labeled Glycoproteins for use as Internal Standards
SBC: GlycoScientific, L.L.C. Topic: 300DESCRIPTION provided by applicant The ability to accurately quantitate the glycan chains attached to glycoproteins has wide ranging implications Numerous studies over the past years have demonstrated that abnormal glycosylation occurs in virtually all types of human cancers and demonstrate the potential of using glycan markers in either a diagnostic or a prognostic manner The glycosylatio ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Scientific Merit and Feasibility of Fructokinase Inhibiton for Obesity
SBC: Colorado Research Partners LLC Topic: NIDDKDESCRIPTION provided by applicant Intake of added sweeteners high fructose corn syrup and sucrose independently predicts the development of obesity metabolic syndrome and diabetes Despite recommendations by WHO and the AHA to reduce sugar intake to to percent of total energy intake the mean intake of added sugars remains percent of the diet and percent of the population ingest ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Manufacturing pathogen inactivated platelet lysate to treat corneal inflammation
SBC: Cambium Medical Technologies LLC Topic: NDESCRIPTION provided by applicant Ocular graft versus host disease O GVHD is a particularly severe and debilitating complication of allogeneic hematopoietic stem cell transplantation HSCT O GVHD develops in of patients with chronic GVHD Currently Restasis cyclosporine A is the only FDA approved prescription topical medication to treat O GVHD In Restasis had sales o ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health